Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999909 | Urologic Oncology: Seminars and Original Investigations | 2013 | 7 Pages |
Abstract
Prognosis in UCB staged pT4a is heterogeneous. Female gender and LVI are adverse factors. Adjuvant chemotherapy seems to improve outcome. The present analysis establishes the first risk model for this demanding tumor stage.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Matthias M.D., Patrick J. M.D., Sabine M.D., Hans-Martin M.D., Derya M.D., Wolfgang M.D., Christian M.D., Christian M.D., Lutz M.D., Edwin M.D., Rudolf M.D., Arne M.D., Stefan C. M.D., Jörg M.D., Alexander M.D., Christian G. M.D., Wolf F. M.D.,